References
- Klugman K, Black S, Dagan R, et al. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th ed. China: Elsevier Saudners; 2013. p. 504–541. Available from: https://www.elsevier.com/books/vaccines/9781455700905.
- Centers for Disease Control and Prevention. Pneumococcal disease. In: Hamborsky J, Kroger A, Wolfe C, editors. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Washington D.C.: Public Health Foundation; 2021. p. 279–296. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pneumo.pdf.
- World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – february 2019. [Internet]. Weekly Epidemiological Record. 2019. Available from: http://www.who.int/immu-%0Ahttps://www.who.int/immunization/policy/position_papers/who_pp_pcv_2019_summary.pdf?ua=1.
- Torres A, Blasi F, Dartois N, et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984–989. Available from https://pubmed.ncbi.nlm.nih.gov/26219979/.
- World Health Organization (WHO). Estimated Hib and pneumococcal deaths for children under 5 years of age, 2000 [Internet]. 2014 [cited 2021 Jan 29]; Available from: https://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib_2000/en/.
- Chapman R, Sutton K, Dillon-Murphy D, et al. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis. Vaccine. 2020;38(45):7138–7145. Available from: https://pubmed.ncbi.nlm.nih.gov/32912642/ .
- Lecrenier N, Marijam A, Olbrecht J, et al. Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (Synflorix) in children. Expert Rev Vaccines. 2020;19(3):247–265. Available from https://pubmed.ncbi.nlm.nih.gov/32195602/ .
- Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–309. Available from: https://pubmed.ncbi.nlm.nih.gov/25656600/.
- Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6(5):e1000081. Available from: https://pubmed.ncbi.nlm.nih.gov/19468297/.
- Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015;33(2):359–366. Available from: https://pubmed.ncbi.nlm.nih.gov/25448105/.
- Waight Pa, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–543. Available from: https://pubmed.ncbi.nlm.nih.gov/25801458/.
- Marom T, Tan A, Wilkinson GS, et al. Trends in otitis media-related health care use in the United States, 2001-2011. JAMA Pediatr. 2014;168(1):68–75. Available from: https://pubmed.ncbi.nlm.nih.gov/24276262/.
- Lau WCY, Murray M, El-Turki A, et al. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine. 2015;33(39):5072–5079. Available from: https://pubmed.ncbi.nlm.nih.gov/26297875/.
- Ben-Shimol S, Givon-Lavi N, Leibovitz E, et al. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clinl Infect Dis. 2014;59(12):1724–1732. Available from: https://pubmed.ncbi.nlm.nih.gov/25159581/.
- Dagan R, van der Beek BA, Ben-Shimol S, et al. Effectiveness of the seven- and thirteen valent pneumococcal conjugate vaccines against vaccine-serotype otitis media. Clinl Infect Dis. 2021;73(4):650–658. Available from: https://pubmed.ncbi.nlm.nih.gov/33507250/.
- Griffin MR, Zhu Y, Moore MR, et al. U.S. Hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(2):155–163. Available from: http://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa1209165.
- Becker-Dreps S, Amaya E, Liu L, et al. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014;33(6):637–642. Available from: https://pubmed.ncbi.nlm.nih.gov/24445827/.
- Angoulvant F, Levy C, Grimprel E, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clinl Infect Dis. 2014;58(7):918–924. Available from: https://pubmed.ncbi.nlm.nih.gov/24532543/.
- Greenberg D, Givon-Lavi N, Ben-Shimol S, et al. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. Vaccine. 2015;33(36):4623–4629. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0264410X15008634.
- Tin Tin Htar M, Van Den Biggelaar AHJ, Sings H, et al. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review. Expert Rev Vaccines. 2019;18(10):1069–1089. Available from: https://pubmed.ncbi.nlm.nih.gov/31585049/.
- Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–e757. Available from: https://pubmed.ncbi.nlm.nih.gov/29903376/ .
- Chen C, Cervero Liceras F, Flasche S, et al. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob Health. 2019;7(1):e58–e67. Available from: https://pubmed.ncbi.nlm.nih.gov/30554762/
- World Health Organization. Time series reported estimates of PCV coverage [Internet]. 2020 [cited 2021 Jan 29]; Available from: https://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragepcv3.html.
- Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19(3):187–195. Available from: https://pubmed.ncbi.nlm.nih.gov/10749457/.
- Lewnard JA, Givon-Lavi N, Dagan R. Dose-specific effectiveness of 7-and 13-Valent pneumococcal conjugate vaccines against vaccine-serotype streptococcus pneumoniae colonization in children. Clinl Infect Dis. 2020;71(8):E289–E300. Available from: https://pubmed.ncbi.nlm.nih.gov/31784753/.
- Andrews N, Kent A, Amin-Chowdhury Z, et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006–2018. Vaccine. 2019;37(32):4491–4498. Available from:https://pubmed.ncbi.nlm.nih.gov/31272872/.
- Desmet S, Verhaegen J, Van Ranst M, et al. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis. 2018;18(8):830–831. Available from: https://pubmed.ncbi.nlm.nih.gov/30001857/.
- Desmet S, Lagrou K, Wyndham-Thomas C, et al. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. Lancet Infect Dis. 2021;21(1):127–136. Available from:https://pubmed.ncbi.nlm.nih.gov/32702303/.
- United Nations Population Division. World population prospects 2019. Data Query: number of births, box sexes combined (thousands) [Internet]. 2019 [cited 2021 Jan 29]; Available from: https://population.un.org/wpp/DataQuery/.
- United Nations Statistical Division. Table 9. Live births and crude birth rates, by urban/rural residence. United Nations Demographic Yearbook. 2018. [cited 2021 Jan 29]. Available from: https://unstats.un.org/unsd/demographic-social/products/dyb/dyb_2017/.
- Dagan R. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation. Expert Rev Vaccines. 2019;18(6):641–661. Available from: https://pubmed.ncbi.nlm.nih.gov/31230486/.
- Centers for Disease Control and Prevention. Direct and Indirect Effects of Routine Vaccination of Children with 7-Valent Pneumococcal Conjugate Vaccine on Incidence of Invasive Pneumococcal Disease - United States, 1998-2003. Morbidity and Mortality Weekly Report. 2005;893–897. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm.
- Shiri T, Datta S, Madan J, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(1):e51–e59. Available from:https://pubmed.ncbi.nlm.nih.gov/27955789/.
- Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451. Available from: https://pubmed.ncbi.nlm.nih.gov/29395999/.
- Ahmed SS, Pondo T, Xing W, et al. Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions-United States. Clinl Infect Dis. 2020;70(12):2484–2492. Available from: https://pubmed.ncbi.nlm.nih.gov/31402387/.
- PopulationPyramid.net. Germany: 2019 [Internet]. 2019 [cited 2021 Jun 24]; Available from: https://www.populationpyramid.net/germany/2019/.
- Wasserman M, Sings HL, Jones D, et al. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Rev Vaccines. 2018;17(1):71–78. Available from: https://pubmed.ncbi.nlm.nih.gov/29164952/.
- Finnish Institute of Health and Welfare. Incidence of invasive pneumococcal disease in Finland [Internet]. 2020 [cited 2021 May 7]; Available from: https://thl.fi/en/web/thlfi-en/research-and-development/research-and-projects/monitoring-the-population-effectiveness-of-pneumococcal-conjugate-vaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland.
- Choi YH, Andrews N, Miller E. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: a modelling study. PLoS Med. 2019;16(7):e1002845. Available from: https://pubmed.ncbi.nlm.nih.gov/31269018/.
- Institut National de Santé Publique du Québec (Comité sur l’immunisation du Québec). Scientific advisory on the optimal schedule for childhood immunization against pneumococcal disease in Québec [Internet]. 2017. [cited 2021 Jan 29]. Available from: https://www.inspq.qc.ca/es/node/11372.
- Public Health England. PCV christmas special vaccine update [Internet]. 2019. [cited 2021 Jan 29]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/852623/PHE_1103_vaccine_update_303_PCV_special_edition_December_2019.pdf.
- Wasserman M, Lucas A, Jones D, et al. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018;146(14):1797–1806. Available from: https://pubmed.ncbi.nlm.nih.gov/30012224/.
- Gouvernement du Québec. Pneumococcal vaccination program [Internet]. 2020 [cited 2021 Mar 9]; Available from: https://www.quebec.ca/en/health/advice-and-prevention/vaccination/pneumococcal-vaccination-program/.
- Kitano T, Aoki H. A model for the incremental burden of invasive Haemophilus influenzae type b due to a decline of childhood vaccination during the COVID-19 outbreak: a dynamic transmission model in Japan. Vaccine. 2021;39(2):343–349. Available from: https://pubmed.ncbi.nlm.nih.gov/33280853/.
- Choi YH, Miller E. Potential impact of Covid-19 response measures on invasive pneumococcal disease in England and Wales. medRxiv. 2020. DOI:https://doi.org/10.1101/2020.06.01.20119057.
- Amin-Chowdhury Z, Aiano F, Mensah A, et al. Impact of the Coronavirus Disease 2019 (COVID-19) pandemic on invasive pneumococcal disease and risk of pneumococcal coinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): prospective National Cohort Study, England. Clinl Infect Dis. 2021;72(5):E65–E75. Available from: https://pubmed.ncbi.nlm.nih.gov/33196783/.
- Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–79. Available from: https://pubmed.ncbi.nlm.nih.gov/20729232/.
- Luotonen J, Herva E, Karma P, et al. The bacteriology of acute otitis media in children with special reference to streptococcus pneumoniae as studied by bacteriological and antigen detection methods. Scand J Infect Dis. 1981;13(3):177–183. Available from: https://pubmed.ncbi.nlm.nih.gov/7313573/.
- Del Beccaro MA, Mendelman PM, Inglis AF, et al. Bacteriology of acute otitis media: a new perspective. J Pediatr. 1992;120(1):81–84. Available from: https://pubmed.ncbi.nlm.nih.gov/1731029/.
- Farkouh RA, Klok RM, Postma MJ, et al. Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines. 2012;11(10):1235–1247. Available from: https://pubmed.ncbi.nlm.nih.gov/23170992/.
- International Vaccines Access Center (IVAC). The evidence base for Pneumococcal Conjugate Vaccines (PCVs): data for decision-making around PCV use in childhood [Internet]. Baltimore (MD); 2017. [cited 2021 Jan 29]. Available from: https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/PCVEvidenceBase-Jan2017.pdf.
- Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;2009(4). Available from: https://pubmed.ncbi.nlm.nih.gov/19821336/.
- Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25(6):494–501. Available from: https://journals.lww.com/00006454-200606000-00006.
- Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25(9):779–781. Available from: https://pubmed.ncbi.nlm.nih.gov/16940833/.
- Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810–815. Available from: https://pubmed.ncbi.nlm.nih.gov/12352800/.
- Griffin MR, Mitchel E, Moore MR, et al. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012. MMWR Morbidity and mortality weekly report. 2014;63( 44):995–998. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25375070.
- Kaboré L, Ouattara S, Sawadogo F, et al. Impact of 13-valent pneumococcal conjugate vaccine on the incidence of hospitalizations for all-cause pneumonia among children aged less than 5 years in Burkina Faso: an interrupted time-series analysis. Inter J Infect Dis. 2020;96:31–38. Available from: https://pubmed.ncbi.nlm.nih.gov/32234344/.
- Berglund A, Ekelund M, Fletcher MA, et al. All-cause pneumonia hospitalizations in children <2 years old in Sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction. PLoS ONE. 2014;9(11):e112211. Available from:https://pubmed.ncbi.nlm.nih.gov/25379659/. https://pubmed.ncbi.nlm.nih.gov/25379659/.
- Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1). Available from: https://pubmed.ncbi.nlm.nih.gov/25734097/.
- Pelton SI, Shea KM, Farkouh RA, et al. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis. 2015;15(1). Available from: https://pubmed.ncbi.nlm.nih.gov/26515134/.
- Leeming JP, Cartwright K, Morris R, et al. Diagnosis of invasive pneumococcal infection by serotype-specific urinary antigen detection. J Clin Microbiol. 2005;43(10):4972–4976. Available from: https://pubmed.ncbi.nlm.nih.gov/16207950/.
- Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol. 2003;41(7):2810–2813. Available from: https://pubmed.ncbi.nlm.nih.gov/12843005/.
- Pride MW, Huijts SM, Wu K, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol. 2012;19(8):1131–1141. Available from: https://pubmed.ncbi.nlm.nih.gov/22675155/.
- Bountogo M, Sanogo B, Pride MW, et al. Application of a pneumococcal serotype-specific urinary antigen detection test for identification of pediatric pneumonia in Burkina Faso. Pediatr Infect Dis J. 2021;40(5):418–425. Available from: https://pubmed.ncbi.nlm.nih.gov/33464020/.
- Sheppard CL, Harrison TG, Smith MD, et al. Development of a sensitive, multiplexed immunoassay using xMAP beads for detection of serotype-specific Streptococcus pneumoniae antigen in urine samples. J Med Microbiol. 2011;60(1):49–55. Available from:https://www-microbiologyresearch-org.eu1.proxy.openathens.net/content/journal/jmm/https://doi.org/10.1099/jmm.0.023150-0.
- Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) Summary Report [Internet]. Atlanta, Georgia; 2019. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2019-06-508.pdf.
- Lessa F. Effectiveness of 13-valent pneumococcal conjugate vaccine in US adults hospitalized with pneumonia, 2014–2017. IDWeek. Washington D.C.; 2019. [cited 2021 Jan 29]. Available from: https://www.eventscribe.com/2019/IDWeek/fsPopup.asp?efp=Q0NRVktHSkw2ODg2&PosterID=229707&rnd=0.479131&mode=posterinfo.
- Lewnard JA, Givon-Lavi N, Weinberger DM, et al. Pan-serotype reduction in progression of streptococcus pneumoniae to Otitis media after rollout of pneumococcal conjugate vaccines. Clin Infect Dis. 2017;65(11):1853–1861. Available from: https://pubmed.ncbi.nlm.nih.gov/29020218/.
- Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10–16. Available from: https://pubmed.ncbi.nlm.nih.gov/12544402/.
- Dagan R, Pelton S, Bakaletz L, et al. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis. 2016;16(4):480–492. Available from: https://pubmed.ncbi.nlm.nih.gov/27036355/.
- Dagan R, Ben-Shimol S, Leibovitz E, et al. Implementation of PCV7/PCV13 in Israel had a significant impact on both pneumococcal and non-pneumococcal complex Otitis Media (OM) rates. IDWeek. Philadelphia, Pennslyvania; 2014. [cited 2021 Jan 29]. Available from: https://idsa.confex.com/idsa/2014/webprogram/Paper45636.html.
- McLaughlin JM, Swerdlow DL, Khan F, et al. Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States. Hum Vaccines Immunother. 2019;15(4):841–849. Available from: https://pubmed.ncbi.nlm.nih.gov/30676236/.
- Vietri J, Harnett J, Emir B, et al. Uptake of 13-Valent pneumococcal conjugate vaccine among US adults aged 19 to 64 years with immunocompromising conditions. Hum Vaccines Immunother. 2020;16(1):161–168. Available from: https://pubmed.ncbi.nlm.nih.gov/31343949/.
- Gavi The Vaccine Alliance. Detailed product profiles [Internet]. 2020 [cited 2021 Jan 20]; Available from: https://www.gavi.org/our-alliance/market-shaping/product-information-vaccines-cold-chain-equipment.
- Gessner BD, Jiang Q, Van Werkhoven CH, et al. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine. 2019;37(38):5777–5787. Available from: https://pubmed.ncbi.nlm.nih.gov/29861177/.
- Wasserman M, Chapman R, Lapidot R, et al. Twenty-Year public health impact of 7- and 13-Valent pneumococcal conjugate vaccines in US children. Emerg Infect Dis. 2021;27(6):1627–1636. Available from: https://wwwnc.cdc.gov/eid/article/27/6/20-4238_article.
- Bloom DE, Kirby PN, Pugh S, et al. Commentary: why has uptake of pneumococcal vaccines for children been so slow? The Perils of undervaluation. Pediatr Infect Dis J. 2020;39(2):145–156. Available from: http://journals.lww.com/https://doi.org/10.1097/INF.0000000000002521.
- Dagan R, Ben-Shimol S, Greenberg D, et al. A prospective, population-based study to determine the incidence and bacteriology of bacterial conjunctivitis in children <2 years of age following 7-valent and 13-valent pneumococcal conjugate vaccine sequential implementation. Clinl Infect Dis. 2021;72(7):1200–1207. Available from: https://academic.oup.com/cid/article/72/7/1200/5782465.
- Murthy BP, Zell E, Kirtland K, et al. Impact of the COVID-19 pandemic on administration of selected routine childhood and adolescent vaccinations — 10 U.S. jurisdictions, march–september 2020. MMWR Morbidity and Mortality Weekly Report. 2021;70( 23):840–845. Available from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7023a2.htm.
- Nunes M. RSV - An annual epidemic. European Society for Paediatric Infectious Diseases. 2021. [cited 2021 Aug 06]. Available from: https://2021.espidmeeting.org/webcasted-industry-sessions/#1622188616813-0e9467ae-5dbf.
- Centers for Disease Control and Prevention. Increased interseasonal Respiratory Syncytial Virus (RSV) activity in parts of the Southern United States [Internet]. CDC Health Alert Network (HAN). 2021; [cited 2021 Aug 06]. Available from: https://emergency.cdc.gov/han/2021/han00443.asp.
- Foley DA, Yeoh DK, Minney-Smith CA, et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2021; [cited 2021 Aug 06]. Available from: https://europepmc.org/articles/PMC7929151.
- Grist JT, Chen M, Collier GJ, et al. Hyperpolarized 129 Xe MRI abnormalities in dyspneic participants 3 months after COVID-19 Pneumonia: preliminary Results. Radiology. 2021:210033. Available from: https://pubs.rsna.org/doi/abs/https://doi.org/10.1148/radiol.2021210033.
- Bloom D, Cadarette D, Ferranna M. The societal value of vaccination in the age of COVID-19. Am J Public Health. 2021;111(6):1049–1054. Available from: https://pubmed.ncbi.nlm.nih.gov/33856880/.